| Not Yet Recruiting | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma NCT07529808 | BigHat Biosciences, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas NCT07290985 | American Association for Cancer Research | Phase 2 |
| Recruiting | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients W NCT07282912 | Yale University | Phase 2 |
| Not Yet Recruiting | Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Inst NCT07266025 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroeso NCT07176312 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Recruiting | A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resec NCT07069712 | AstraZeneca | Phase 2 |
| Recruiting | Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) NCT05733689 | University of California, Irvine | Phase 1 |
| Recruiting | A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer NCT06921837 | Bolt Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ NCT06985602 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Recruiting | Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease NCT06529822 | Washington University School of Medicine | Phase 1 |
| Recruiting | A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or NCT06767800 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants NCT06469944 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Recruiting | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker- NCT06445972 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Recruiting | Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma NCT06043427 | Canadian Cancer Trials Group | Phase 2 |
| Terminated | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. NCT05977322 | Novartis Pharmaceuticals | Phase 1 |
| Not Yet Recruiting | The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negativ NCT05986227 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-posit NCT05152147 | Jazz Pharmaceuticals | Phase 3 |
| Terminated | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. NCT04712721 | Novartis Pharmaceuticals | EARLY_Phase 1 |
| Active Not Recruiting | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors NCT05029882 | AbbVie | Phase 1 |
| Withdrawn | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With NCT04602117 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Active Not Recruiting | Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First NCT04021108 | Weill Medical College of Cornell University | Phase 2 |
| Completed | A Study of a Personalized Neoantigen Cancer Vaccine NCT03639714 | Gritstone bio, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Personalized Neoantigen Cancer Vaccines NCT03794128 | Gritstone bio, Inc. | — |
| Completed | Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma NCT01757171 | Weill Medical College of Cornell University | Phase 2 |
| Terminated | Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adeno NCT01182610 | Accelerated Community Oncology Research Network | Phase 2 |
| Completed | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck o NCT01045421 | Millennium Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer NCT00073502 | OSI Pharmaceuticals | Phase 2 |